Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olivier Lambotte

Showing results (1-10 of 307) with videos related to

Pageof 31
Sort By:
Medecine Sciences : M/S|March 2, 2012
[HIV controllers: how these patients control viral replication?]Olivier Lambotte
Medecine Sciences : M/S|May 23, 2023
[An overview of immune checkpoint inhibitors toxicities]Guillaume Rouvet, Olivier Lambotte
Current Opinion in Oncology|January 27, 2025
Long-term immune related adverse eventsLeo Plaçais, Olivier Lambotte
La Revue Du Praticien|January 23, 2026
[Hemophagocytic lymphohistiocytosis]Aude Mausoleo, Olivier Lambotte
Current Opinion in HIV and AIDS|February 26, 2026
The elite controller phenotypeNicolas Noel, Olivier Lambotte
Current Opinion in HIV and AIDS|April 20, 2011
Epidemiology and clinical characteristics of elite controllersJason F Okulicz, Olivier Lambotte
Brain Pathology (Zurich, Switzerland)|February 13, 2003
HIV-1 persistence, viral reservoir, and the central nervous system in the HAART eraOlivier Lambotte, Kumaran Deiva, Marc Tardieu
La Revue Du Praticien|April 16, 2019
[Management of adverse events associated with cancer immunotherapy]Stéphane Champiat, Jean-Marie Michot, Olivier Lambotte
Internal and Emergency Medicine|March 8, 2020
Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approachJeanne de La Rochefoucauld, Nicolas Noël, Olivier Lambotte
La Revue Du Praticien|June 23, 2021
[Management of adverse events associated with cancer immunotherapy]Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Pageof 31

Showing results (1-10 of 307) with videos related to

Sort By:
Pageof 31
Medecine Sciences : M/S|March 2, 2012
[HIV controllers: how these patients control viral replication?]Olivier Lambotte
Medecine Sciences : M/S|May 23, 2023
[An overview of immune checkpoint inhibitors toxicities]Guillaume Rouvet, Olivier Lambotte
Current Opinion in Oncology|January 27, 2025
Long-term immune related adverse eventsLeo Plaçais, Olivier Lambotte
La Revue Du Praticien|January 23, 2026
[Hemophagocytic lymphohistiocytosis]Aude Mausoleo, Olivier Lambotte
Current Opinion in HIV and AIDS|February 26, 2026
The elite controller phenotypeNicolas Noel, Olivier Lambotte
Current Opinion in HIV and AIDS|April 20, 2011
Epidemiology and clinical characteristics of elite controllersJason F Okulicz, Olivier Lambotte
Brain Pathology (Zurich, Switzerland)|February 13, 2003
HIV-1 persistence, viral reservoir, and the central nervous system in the HAART eraOlivier Lambotte, Kumaran Deiva, Marc Tardieu
La Revue Du Praticien|April 16, 2019
[Management of adverse events associated with cancer immunotherapy]Stéphane Champiat, Jean-Marie Michot, Olivier Lambotte
Internal and Emergency Medicine|March 8, 2020
Management of immune-related adverse events associated with immune checkpoint inhibitors in cancer patients: a patient-centred approachJeanne de La Rochefoucauld, Nicolas Noël, Olivier Lambotte
La Revue Du Praticien|June 23, 2021
[Management of adverse events associated with cancer immunotherapy]Ariane Laparra, Stéphane Champiat, Jean-Marie Michot, et al.
Pageof 31